Endocrine Abstracts

J J Kopchick, Ohio University, Athens, Ohio, USA. AbstractDr John J Kopchick is an internationally recognized leader in the growth hormone (GH) field. Since 1987, he has held the Milton and Lawrence H Goll Eminent Scholar Professorship in Molecular and Cellular Biology and directs the Growth/Obesity/Diabetes Section of the Edison Biotechnology Institute at Ohio University in Athens, Ohio. He also is Professor in the B...

Pegvisomant is a specific GH antagonist developed for the treatment of acromegaly. Pegvisomant is a GH antagonist molecule with an amino acid substitution that blocks the conformational change necessary for signal transduction and polyethylene glycol (PEG) moieties to improve clinical efficacy. Pegvisomant has a long plasma half-life and its mode of clearance has not been established. We hypothesised that GHR mediated internalisation of Pegvisomant might be one mechanism for i...

Introduction:Hepatic IGF-I is generally believed to be regulated by pituitary-derived GH. However recent studies have emphasized the importance of paracrine/autocrine IGF-I in normal growth and development, as well as some malignancies. However, it remains unclear how locally produced IGF-I is regulated. The aim of this project was to investigate IGF-I expression in different tissues from the growth hormone receptor knock-out (GHR-KO) mouse.<p class=...